JPWO2019199792A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019199792A5 JPWO2019199792A5 JP2020555352A JP2020555352A JPWO2019199792A5 JP WO2019199792 A5 JPWO2019199792 A5 JP WO2019199792A5 JP 2020555352 A JP2020555352 A JP 2020555352A JP 2020555352 A JP2020555352 A JP 2020555352A JP WO2019199792 A5 JPWO2019199792 A5 JP WO2019199792A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- allosteric
- formula
- pharmaceutically acceptable
- shp2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862655648P | 2018-04-10 | 2018-04-10 | |
| US62/655,648 | 2018-04-10 | ||
| PCT/US2019/026543 WO2019199792A1 (en) | 2018-04-10 | 2019-04-09 | Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521155A JP2021521155A (ja) | 2021-08-26 |
| JP2021521155A5 JP2021521155A5 (https=) | 2022-04-07 |
| JPWO2019199792A5 true JPWO2019199792A5 (https=) | 2022-04-07 |
Family
ID=66248820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555352A Pending JP2021521155A (ja) | 2018-04-10 | 2019-04-09 | Ｓｈｐ２阻害剤組成物、癌を処置するための方法、およびｓｈｐ変異を有する対象を特定するための方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210154190A1 (https=) |
| EP (1) | EP3773590A1 (https=) |
| JP (1) | JP2021521155A (https=) |
| KR (1) | KR20200143417A (https=) |
| CN (1) | CN112203689A (https=) |
| AU (1) | AU2019251207A1 (https=) |
| BR (1) | BR112020020743A2 (https=) |
| CA (1) | CA3096535A1 (https=) |
| CO (1) | CO2020012588A2 (https=) |
| IL (1) | IL277783B2 (https=) |
| MX (1) | MX2020010719A (https=) |
| SG (1) | SG11202009793TA (https=) |
| TW (1) | TW201946627A (https=) |
| WO (1) | WO2019199792A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| AU2017274199B2 (en) | 2016-05-31 | 2021-09-23 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| MX383856B (es) | 2016-06-14 | 2025-03-14 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de shp2. |
| KR102598895B1 (ko) | 2016-07-12 | 2023-11-07 | 레볼루션 메디슨즈, 인크. | 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진 |
| US11529347B2 (en) | 2016-09-22 | 2022-12-20 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
| TW202500565A (zh) | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| MX2019008695A (es) | 2017-01-23 | 2019-09-11 | Revolution Medicines Inc | Compuestos biciclicos como inhibidores alostericos de shp2. |
| MX2019008696A (es) | 2017-01-23 | 2019-09-13 | Revolution Medicines Inc | Compuestos de piridina como inhibidores de shp2 alostericos. |
| WO2018218133A1 (en) | 2017-05-26 | 2018-11-29 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| MX2020003579A (es) | 2017-10-12 | 2020-07-22 | Revolution Medicines Inc | Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos. |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| SG11202009245TA (en) | 2018-03-21 | 2020-10-29 | Relay Therapeutics Inc | Shp2 phosphatase inhibitors and methods of use thereof |
| WO2019183364A1 (en) | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
| KR102611661B1 (ko) | 2018-05-02 | 2023-12-08 | 나비레 파르마, 인코퍼레이티드 | Ptpn11의 치환된 헤테로사이클릭 억제제 |
| LT3833670T (lt) | 2018-08-10 | 2024-06-25 | Navire Pharma, Inc. | 6-(4-amino-3-metil-2-oksa-8-azaspiro[4.5]dekan-8-il)-3-(2,3-dichlorfenil)-2-metilpirimidin-4(3h)-ono dariniai ir susiję junginiai kaip ptpn11 (shp2) inhibitoriai, skirti vėžiui gydyti |
| WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| CN111138412B (zh) | 2018-11-06 | 2023-09-15 | 上海奕拓医药科技有限责任公司 | 一种螺芳环化合物及其应用 |
| CN111647000B (zh) | 2019-03-04 | 2021-10-12 | 勤浩医药（苏州）有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
| EP3980128A1 (en) | 2019-06-07 | 2022-04-13 | Revolution Medicines, Inc. | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor |
| AU2020354475A1 (en) | 2019-09-24 | 2022-05-05 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of making and using the same |
| CN112724145A (zh) * | 2019-10-14 | 2021-04-30 | 杭州雷索药业有限公司 | 用于抑制shp2活性的吡嗪衍生物 |
| TW202128688A (zh) | 2019-11-08 | 2021-08-01 | 美商銳新醫藥公司 | 雙環雜芳基化合物及其用途 |
| WO2021110796A1 (en) * | 2019-12-04 | 2021-06-10 | Bayer Aktiengesellschaft | Inhibitors of shp2 |
| CN111265529B (zh) * | 2020-02-22 | 2021-07-23 | 南京大学 | 蛋白酪氨酸磷酸酶shp2抑制剂在制备治疗银屑病药物中的应用 |
| WO2021171261A1 (en) | 2020-02-28 | 2021-09-02 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor |
| IL308234A (en) | 2021-05-05 | 2024-01-01 | Huyabio Int Llc | Monotherapy with an SHP2 inhibitor and its uses |
| CA3217084A1 (en) | 2021-05-05 | 2022-11-10 | Farbod Shojaei | Combination therapies comprising shp2 inhibitors and pd-1 inhibitors |
| CN114716448B (zh) * | 2021-05-13 | 2024-01-30 | 中国科学院上海药物研究所 | 抑制shp2活性的杂环化合物、其制备方法及用途 |
| WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| CA3224341A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| CN116063307B (zh) | 2021-10-29 | 2025-08-19 | 中国药科大学 | Shp2与cdk4/6双靶点抑制化合物合成及其制备方法与应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| WO2003029422A2 (en) * | 2001-10-01 | 2003-04-10 | Mount Sinai School Of Medicine | Noonan syndrome gene |
| ES2577535T3 (es) * | 2005-10-21 | 2016-07-15 | Regents Of The University Of California | Mutaciones del oncogén de C-kit en melanomas |
| KR101906146B1 (ko) | 2009-08-17 | 2018-10-10 | 메모리얼 슬로안-케터링 캔서 센터 | 열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법 |
| US8673913B2 (en) * | 2009-11-13 | 2014-03-18 | Case Western Reserve University | SHP-2 phosphatase inhibitor |
| EP2826586A1 (en) | 2013-07-18 | 2015-01-21 | Siemens Aktiengesellschaft | A method and a system for machining an object |
| JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| CN105899493B (zh) | 2014-01-17 | 2019-03-29 | 诺华股份有限公司 | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 |
| JP6523303B2 (ja) | 2014-01-17 | 2019-05-29 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物 |
| ES2824576T3 (es) | 2015-06-19 | 2021-05-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| CN112625028B (zh) | 2015-06-19 | 2024-10-29 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
| ES2741746T3 (es) | 2015-06-19 | 2020-02-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| US11008372B2 (en) | 2015-11-07 | 2021-05-18 | Board Of Regents, The University Of Texas System | Targeting proteins for degradation |
| WO2017156397A1 (en) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Heterocyclic inhibitors of ptpn11 |
| EA202092441A1 (ru) | 2016-06-07 | 2021-05-21 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| KR102598895B1 (ko) * | 2016-07-12 | 2023-11-07 | 레볼루션 메디슨즈, 인크. | 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진 |
-
2019
- 2019-04-09 SG SG11202009793TA patent/SG11202009793TA/en unknown
- 2019-04-09 JP JP2020555352A patent/JP2021521155A/ja active Pending
- 2019-04-09 BR BR112020020743-8A patent/BR112020020743A2/pt not_active IP Right Cessation
- 2019-04-09 CN CN201980037528.7A patent/CN112203689A/zh active Pending
- 2019-04-09 CA CA3096535A patent/CA3096535A1/en active Pending
- 2019-04-09 IL IL277783A patent/IL277783B2/en unknown
- 2019-04-09 AU AU2019251207A patent/AU2019251207A1/en not_active Abandoned
- 2019-04-09 EP EP19719088.7A patent/EP3773590A1/en not_active Withdrawn
- 2019-04-09 WO PCT/US2019/026543 patent/WO2019199792A1/en not_active Ceased
- 2019-04-09 KR KR1020207032251A patent/KR20200143417A/ko not_active Ceased
- 2019-04-09 MX MX2020010719A patent/MX2020010719A/es unknown
- 2019-04-09 TW TW108112247A patent/TW201946627A/zh unknown
-
2020
- 2020-10-06 US US17/064,317 patent/US20210154190A1/en not_active Abandoned
- 2020-10-09 CO CONC2020/0012588A patent/CO2020012588A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019199792A5 (https=) | ||
| JP2021521155A5 (https=) | ||
| JP7058345B2 (ja) | Ｂｃｌ－２阻害剤及びＭＤＭ２阻害剤の組合せ製品並びに疾患の予防及び／又治療におけるその使用 | |
| JP2022508055A (ja) | サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤 | |
| JP7328323B2 (ja) | ＳＭＡＲＣＡ２／ＢＲＭ ＡＴＰａｓｅ阻害剤としての尿素化合物及び組成物 | |
| TW202333714A (zh) | 包含喹唑啉化合物之醫藥組成物 | |
| JP2020508302A5 (https=) | ||
| CA3180314A1 (en) | Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9 | |
| IL277783B2 (en) | Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations | |
| BRPI0810911A2 (pt) | Compostos com atividade anticâncer | |
| TW200932239A (en) | PARP inhibitor compounds, compositions and methods of use | |
| CN117794929A (zh) | 选择性bcl-xl protac化合物及使用方法 | |
| US11459306B2 (en) | Compounds, compositions, and methods for treating T-cell acute lymphoblastic leukemia | |
| JP2024056937A (ja) | Ｒａｓ腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法 | |
| CN104379565B (zh) | 氨基吡啶衍生物的癌预防或治疗用途 | |
| JP2025541823A (ja) | Ｄｎａポリメラーゼシータ阻害剤としてのチアジアゾリル誘導体およびその使用 | |
| JP2019506382A (ja) | 癌及びウイルスを阻害するための化合物 | |
| TW201932111A (zh) | 用於治療癌症之組合療法 | |
| ES2560260T3 (es) | Moduladores de Aurora y FLT3 quinasas | |
| WO2022028429A1 (zh) | 用于根除癌症干细胞并诱导damp介导的抗肿瘤免疫反应的一组新型copi/arf1-脂解途径抑制剂和化合物 | |
| US12275725B2 (en) | Inhibitors of the notch transcriptional activation complex and methods for use of the same | |
| JP6853833B2 (ja) | エストロゲン受容体調節物質の組合せ | |
| US20140073637A1 (en) | Amino-substituted-alkyloxy-benzo[e]pyrido[4,3-b]indole derivatives as new potent kinase inhibitors | |
| US20240034742A1 (en) | Dosing regimens for cyclin-dependent kinase 7 (cdk7) inhibitors | |
| WO2026044133A1 (en) | Methods and compositions for the treatment of cancer |